Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

As science soars with game-changing HIV tools, a funding crisis threatens to ground progress "We come together at a pivotal time for the HIV response, one defined by both incredible scientific ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...